Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer

  • Kim, Yeon Joo (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Song, Si Yeol (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jeong, Seong-Yun (Institute of Innovative Science, Asan Medical Center) ;
  • Kim, Sang We (Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jung-Shin (Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Su Ssan (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Wonsik (Department of Radiation Oncology, Gangneung Asan Hospital) ;
  • Choi, Eun Kyung (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.10.07
  • Accepted : 2015.12.09
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To determine failure patterns and survival outcomes of T4N0-1 non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. Materials and Methods: Ninety-five patients with T4N0-1 NSCLC who received definitive radiotherapy with or without chemotherapy from May 2003 to October 2014 were retrospectively reviewed. The standard radiotherapy scheme was 66 Gy in 30 fractions. The main concurrent chemotherapy regimen was $50mg/m^2$ weekly paclitaxel combined with $20mg/m^2$ cisplatin or AUC 2 carboplatin. The primary outcome was overall survival (OS). Secondary outcomes were failure patterns and toxicities. Results: The median age was 64 years (range, 34 to 90 years). Eighty-eight percent of patients (n = 84) had an Eastern Cooperative Oncology Group performance status of 0-1, and 42% (n = 40) experienced pretreatment weight loss. Sixty percent of patients (n = 57) had no metastatic regional lymph nodes. The median radiation dose was EQD2 67.1 Gy (range, 56.9 to 83.3 Gy). Seventy-one patients (75%) were treated with concurrent chemotherapy; of these, 13 were also administered neoadjuvant chemotherapy. At a median follow-up of 21 months (range, 1 to 102 months), 3-year OS was 44%. The 3-year cumulative incidences of local recurrence and distant recurrence were 48.8% and 36.3%, respectively. Pretreatment weight loss and combined chemotherapy were significant factors for OS. Acute esophagitis over grade 3 occurred in three patients and grade 3 chronic esophagitis occurred in one patient. There was no grade 3-4 radiation pneumonitis. Conclusion: Definitive radiotherapy for T4N0-1 NSCLC results in favorable survival with acceptable toxicity rates. Local recurrence is the major recurrence pattern. Intensity modulated radiotherapy and radio-sensitizing agents would be needed to improve local tumor control.

Keywords

References

  1. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5. https://doi.org/10.1056/NEJM199010043231403
  2. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205. https://doi.org/10.1093/jnci/87.3.198
  3. Curran WJ. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLS: RTOG 94-10. In: 2003 Annual Meeting of the American Society of Clinical Oncology; 2003 June 1; Chicago, IL, USA. Alexandria, VA: ASCO; 2003.
  4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9. https://doi.org/10.1200/JCO.1999.17.9.2692
  5. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8. https://doi.org/10.1056/NEJM199401203300301
  6. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92. https://doi.org/10.1200/JCO.1995.13.8.1880
  7. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86. https://doi.org/10.1016/S0140-6736(09)60737-6
  8. Reymen B, van Baardwijk A, Wanders R, et al. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiother Oncol 2014;110:482-7. https://doi.org/10.1016/j.radonc.2013.12.005
  9. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e314S-40S. https://doi.org/10.1378/chest.12-2360
  10. Wu L, Xu Z, Zhao X, et al. Surgical treatment of lung cancer invading the left atrium or base of the pulmonary vein. World J Surg 2009;33:492-6. https://doi.org/10.1007/s00268-008-9873-5
  11. Garrido P, Gonzalez-Larriba JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:4736-42. https://doi.org/10.1200/JCO.2007.12.0014
  12. Chambers A, Routledge T, Bille A, Scarci M. Does surgery have a role in T4N0 and T4N1 lung cancer? Interact Cardiovasc Thorac Surg 2010;11:473-9. https://doi.org/10.1510/icvts.2010.235119
  13. Park J, Song SY, Kim SS, et al. Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer. Radiat Oncol J 2014;32:70-6. https://doi.org/10.3857/roj.2014.32.2.70
  14. Pitz CC, Brutel de la Riviere A, van Swieten HA, Westermann CJ, Lammers JW, van den Bosch JM. Results of surgical treatment of T4 non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 24:1013-8. https://doi.org/10.1016/S1010-7940(03)00493-7
  15. Bradley JD. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617. In: 49th Annual Meeting of the American Society of Clinical Oncology; 2013 June 7; Chicago, IL, USA. Alexandria, VA: ASCO; 2013.
  16. Rodrigues G, Oberije C, Senan S, et al. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. Int J Radiat Oncol Biol Phys 2015;91:133-9. https://doi.org/10.1016/j.ijrobp.2014.09.033
  17. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatmentrelated pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:94-102. https://doi.org/10.1016/j.ijrobp.2006.12.031
  18. Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999;52:129-36. https://doi.org/10.1016/S0167-8140(99)00093-6
  19. Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20: 4191-8. https://doi.org/10.1200/JCO.2002.03.054
  20. Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer 2015; 87:232-40. https://doi.org/10.1016/j.lungcan.2014.12.003
  21. Bergs JW, Wacker MG, Hehlgans S, et al. The role of recent nanotechnology in enhancing the efficacy of radiation therapy. Biochim Biophys Acta 2015;1856:130-43.
  22. Pfannenberg AC, Aschoff P, Brechtel K, et al. Low dose nonenhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:36-44. https://doi.org/10.1007/s00259-006-0186-3
  23. Chheang S, Brown K. Lung cancer staging: clinical and radiologic perspectives. Semin Intervent Radiol 2013;30:99-113. https://doi.org/10.1055/s-0033-1342950

Cited by

  1. Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage III non-small cell lung cancer vol.9, pp.None, 2015, https://doi.org/10.2147/ott.s124311
  2. Study on the Dose Uncertainties in the Lung during Passive Proton Irradiation with a Proton Beam Range Compensator vol.72, pp.11, 2015, https://doi.org/10.3938/jkps.72.1369
  3. Construction of Radiation Surviving/Resistant Lung Cancer Cell Lines with Equidifferent Gradient Dose Irradiation vol.18, pp.4, 2020, https://doi.org/10.1177/1559325820982421